Back to search

National and Kapodistrian University of Athens

Συγκριτική μελέτη των επιπέδων της βιταμίνης D σε ασθενείς με ιδιοπαθή πνευμονική ίνωση, λοιπές ιδιοπαθείς διάμεσες πνευμονοπάθειες και διάμεσες πνευμονοπάθειες που σχετίζονται με νοσήματα του συνδετικού ιστού

Abstract

dc:description

Vitamin D (VitD) is a steroid hormone with cytoprotective and anti-inflammatory properties. Epidemiological studies have suggested a link between VitD deficiency and risk of development of chronic lung diseases. Its role in lung fibrosis is largely unknown. The aim of our study was to investigate the role of VitD in experimental and human lung fibrosis.METHODS: VitD (25-OH-D3, 2 μg/kg) was orally administered from day 3-day 13 following bleomycin-challenge, in 8-10 weeks-old C57/BL6 mice. Mouse Lung Fibroblasts (MLFs) were pre-treated with VitD (2 μM for 24 h) and then stimulated with TGFB1 (10 ng/ml). Serum samples from 93 patients with IPF and other forms of interstitial lung diseases (ILDs) were prospectively collected for VitD measurement.RESULTS: VitD administration prevented bleomycin-induced lung fibrosis, as assessed by reductions in hydroxyproline levels, mRNA levels of col1a1, col3a1 and a-SMA (1.4-, 3.1-, 2.25-, 2.5-fold, respectively) and Masson Trichrome staining compared to the untreated group and these changes were associated with restoration of the bleomycin-induced down regulation of vitamin D-receptor (Vdr) mRNA levels. Pretreatment with VitD reduced the responsiveness of MLFs to pro-fibrotic stimuli, as indicated by significant decreases of col1a1, col3a1 and a-SMA (3.6-, 4.1- and 2.7-fold, respectively).These changes were associated with restoration of the TGFB1-induced downregulation of vitamin D-receptor (VDR) mRNA levels. VitD treatment deactivated TGFB1-induced Smad3 phosphorylation. Patients with IPF and other forms of ILDs displayed deficient VitD serum concentrations (mean VitD = 18.76 ± 8.36 vs. 18.54 ± 8.39 ng/ml, respectively, p = 0.9). VitD deficiency was correlated with baseline FVC%predicted (r = 0.47, p < 0.0001), DLCO%predicted (r = 0.6, p < 0.0001), GAP score (r = -0.4, p < 0.0001) and all-cause mortality in patients with IPF (HR: 3.7, p = 0.001). CONCLUSIONS: VitD could serve as a prognosticator and potential therapeutic target in patients with IPF. Further studies are sorely needed.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tzilas, Vasilios
  • Τζίλας, Βασίλειος

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/45063

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tzilas, Vasilios; Τζίλας, Βασίλειος. Συγκριτική μελέτη των επιπέδων της βιταμίνης D σε ασθενείς με ιδιοπαθή πνευμονική ίνωση, λοιπές ιδιοπαθείς διάμεσες πνευμονοπάθειες και διάμεσες πνευμονοπάθειες που σχετίζονται με νοσήματα του συνδετικού ιστού. National and Kapodistrian University of Athens, 2019. http://hdl.handle.net/10442/hedi/45063